Company intelligence / Profile preview
Monarch Therapeutics
Princeton, New Jersey, USAmonarchtherapeutics.com ↗
- Ownership
- Private
- Employees
- ~2
- Development stage
- Preclinical
01
Overview
Monarch Therapeutics has not yet reported clinical results. The company’s lead multi-targeted adoptive cell therapy program for metastatic ovarian cancer is entering IND-enabling studies in 2024. The company aims to address solid tumor heterogeneity and immunosuppressive environments using its proprietary adaptor-CAR platform technology.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Adoptive cell therapyadoptive drug conjugatesadaptor-CAR technology
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Monarch Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Monarch Therapeutics.